POP Biotechnologies announced the commencement of two Phase 3 clinical studies of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics. EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's spontaneous-nanoliposome antigen particle (SNAP) technology.
EuBiologics announced last month that it was selected to receive a Korean National New Drug Development Foundation of the Ministry of Health and Welfare grant that will enable EuCorVac-19 to be tested in a Phase III comparison trial in 4,000 healthy participants in the Philippines. This follows prior news that EuBiologics already initiated a separate Phase III clinical trial of EuCorVac-19 in the Democratic Republic of Congo in June and intends to combine the results of this one with the recently announced trials. EuBiologics will work closely with international research organizations to expedite recruitment in countries with low vaccination rates and analyze trial results to accelerate the regulatory approval and commercialization of EuCorVac-19.
The successful completion of Phase III trials could further validate POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. This will enable further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 in the future. "This Phase III trial is a monumental step forward for our technology. Achieving this critical milestone provides validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform's development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide," says POP BIO President and co-founder Jonathan Smyth.
EuCorVac-19 has already been shown to be safe and effective in a Phase I/II clinical trial, the results of which were announced in December 2021. EuBiologics expects to expedite the development of an Omicron variant booster vaccine based on the same platform used for EuCorVac-19. A booster vaccine is necessary due to the dominance of emerging virus variants.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!